Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “glp1 Agonist”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06548490
What this trial is testing

GLP-1R Agonist Treatment for Opioid Use Disorder

Who this might be right for
Opioid Use DisorderOpioid Abuse and AddictionNarcotic-Related Disorders+4 more
Milton S. Hershey Medical Center 200
Not applicableLooking for participantsNCT07653412
What this trial is testing

Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

Who this might be right for
Obesity (Disorder)Anti-obesity AgentsPrecision Medicine
National and Kapodistrian University of Athens 220
Testing effectiveness (Phase 2)WithdrawnNCT03371862
What this trial is testing

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Who this might be right for
Short Bowel Syndrome
Imperial College London
Not applicableNot Yet RecruitingNCT06927401
What this trial is testing

Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users

Who this might be right for
Endoscopy, Digestive SystemGLP1-R-related Disease
Asian Institute of Gastroenterology, India 36
Testing effectiveness (Phase 2)Looking for participantsNCT07523633
What this trial is testing

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Who this might be right for
Cannabis Use DisorderCannabis Use DisordersCannabis Abuse+2 more
Anders Fink-Jensen, MD, DMSci 100
Post-approval studies (Phase 4)Not Yet RecruitingNCT07027969
What this trial is testing

Metabolic Surgery for Atrial Fibrillation Elimination

Who this might be right for
Atrial FibrillationObesity and Obesity-related Medical Conditions
Ali Aminian 100
Testing effectiveness (Phase 2)UnknownNCT04615871
What this trial is testing

Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

Who this might be right for
Covid19Myocardial Injury
Vladimír Džavík 400
Post-approval studies (Phase 4)Study completedNCT03361098
What this trial is testing

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Who this might be right for
Type 2 Diabetes MellitusObesity
Amsterdam UMC, location VUmc 65
Large-scale testing (Phase 3)Looking for participantsNCT07282041
What this trial is testing

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

Who this might be right for
Intracranial AtherosclerosisStroke, Ischemic
National University of Singapore 130
Not applicableStudy completedNCT07360262
What this trial is testing

Gastric Emptying Recovery After GLP-1 RA Cessation

Who this might be right for
Gastric EmptyingGastroparesisPreoperative Care
Wonkwang University Hospital 186
Not applicableStudy completedNCT07281196
What this trial is testing

Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

Who this might be right for
Sleep Apnea Syndrome (OSAS)
Shanghai Fengxian District Central Hospital 15
Testing effectiveness (Phase 2)Study completedNCT06500429
What this trial is testing

Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

Who this might be right for
Overweight and ObesityHealthy
Neurogastrx, Inc. 120
Not applicableNot Yet RecruitingNCT07787936
What this trial is testing

GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

Who this might be right for
Heart Failure With Preserved Ejection FractionObesityDiastolic Heart Failure+2 more
Miedziowe Centrum Zdrowia SA 150
Not applicableNot Yet RecruitingNCT07817823
What this trial is testing

Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss

Who this might be right for
Overweight and Obesity in Adults Receiving GLP-1RA Treatment
Huazhong University of Science and Technology 200
Not applicableEnrolling By InvitationNCT06924697
What this trial is testing

Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients

Who this might be right for
Diabetes Mellitus, Type 2Nicotine Dependence, Cigarettes
Shanghai East Hospital 46
Post-approval studies (Phase 4)Enrolling By InvitationNCT07117240
What this trial is testing

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

Who this might be right for
Steroid-Induced DiabetesSteroid-Induced HyperglycemiaDiabetes
Medical University of Warsaw 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07021937
What this trial is testing

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Who this might be right for
Obesity/Therapy
University of Colorado, Denver 120
Not applicableStudy completedNCT06660134
What this trial is testing

Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)Atrial Fibrillation (AF)
Shanghai Chest Hospital 174
Not applicableNot Yet RecruitingNCT07720466
What this trial is testing

Salivary Function and Dental Changes During GLP-1 Therapy

Who this might be right for
ObesityDental ErosionSaliva Collection+1 more
Bilecik Seyh Edebali Universitesi 40
Large-scale testing (Phase 3)Study completedNCT00707031
What this trial is testing

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Who this might be right for
Diabetes Mellitus, Type 2
Sanofi 639
Next Page